Rakovina Therapeutics Inc. has unveiled promising preclinical data from two lead programs at the 2026 AACR Annual Meeting, showcasing advancements in AI-driven cancer therapies targeting DNA damage response (DDR) vulnerabilities in solid tumors. The first program focuses on a novel brain-penetrant dual ATR-mTOR inhibitor specifically designed for PTEN-deficient cancers, which represent a significant portion of gliomas and metastatic breast cancers. This dual inhibition strategy addresses the dual vulnerabilities arising from PTEN loss, with the candidate demonstrating potent enzymatic inhibition, selectivity, and in vivo efficacy in preclinical models, outperforming established reference compounds in tolerability.

The second program involves the development of a lipid nanoparticle formulation for kt-3283, a bifunctional PARP and HDAC inhibitor. This formulation aims to enhance bioavailability and metabolic stability, overcoming limitations that have previously hindered the clinical viability of kt-3283. Preclinical characterization confirmed the successful assembly of lipid nanoparticles with properties conducive to improved cellular uptake, setting the stage for further biological evaluation.

These findings suggest a significant shift in the approach to drug development for challenging cancer types. The integration of AI-guided design with biological validation is not only accelerating the identification of lead candidates but also enhancing their therapeutic profiles. This dual focus on CNS penetrance and reduced toxicity could streamline the path toward IND-enabling studies, potentially altering timelines for bringing effective therapies to clinical trials. Rakovina’s approach exemplifies the potential of AI in revolutionizing cancer therapeutics, particularly in addressing unmet needs in treating hard-to-target tumors.

Source: globenewswire.com